Crystalline form of the compound A-348441

US8124129B2 · kind B2 · utility

Assignee

• Karo Bio AB · SE

Inventors

• Russell D. Cink · Grayslake, US
• Daozhong Zou · Bound Brook, US
• Marvin R. Leanna · Grayslake, US
• Pascal H. Toma · Cary, US
• Michelle A. Long · Lombard, US

Key dates

• Filing date: Jul 12, 2006
• Grant date: Feb 28, 2012
• Expiry date: May 28, 2028

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P9/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

There is provided a hemihydrate of (3β,5β,7α,12α)-7,12-dihydroxy-3-{2-[{4-[17β-hydroxy-3-oxo-17α-prop-1-ynylestra-4,9-dien-11β-yl]phenyl}(methyl)amino]ethoxy}cholan-24-oic acid in a crystalline form which is characterised by an X-ray diffraction pattern having major peaks at 2θ=6.58±0.2, 8.54+0.2, 12.28±0.2, and 19.68±0.2. This crystalline material is useful in the treatment of conditions associated with an excess of hepatic glucocorticoid response.